CATB Catabasis Pharmaceuticals Inc.

6.08
+0.03  (+1%)
Previous Close 6.05
Open 6.15
Price To Book 1.63
Market Cap 70,632,041
Shares 11,617,112
Volume 28,121
Short Ratio
Av. Daily Volume 57,700

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data due 2H 2020.
Edasalonexent (CAT-1004)
Duchenne muscular dystrophy (DMD)
Phase 2a did not meet primary endpoint - June 2016
CAT-2054
Hypercholesterolemia

Latest News

  1. Edited Transcript of CATB earnings conference call or presentation 8-Aug-19 12:30pm GMT
  2. Catabasis Pharmaceuticals Reports Second Quarter 2019 Financial Results and Reviews Business Progress
  3. Catabasis Pharmaceuticals Appoints Hugh M. Cole to its Board of Directors
  4. Catabasis Pharmaceuticals to Present at 2019 Wedbush PacGrow Healthcare Conference
  5. Catabasis Pharmaceuticals to Report Second Quarter 2019 Financial Results and Recent Corporate Developments on Thursday, August 8th
  6. Does Catabasis Pharmaceuticals, Inc.'s (NASDAQ:CATB) CEO Pay Reflect Performance?
  7. Catabasis Pharmaceuticals Provides Update on Global Phase 3 PolarisDMD Trial for Edasalonexent at Parent Project Muscular Dystrophy 25th Annual Conference
  8. Catabasis Pharmaceuticals Presents Preclinical Data Showing Potential for Bone Preservation with Edasalonexent in Duchenne Muscular Dystrophy
  9. Catabasis Pharmaceuticals to Present at Upcoming Symposium on Muscle-Bone Interaction in Duchenne Muscular Dystrophy and Parent Project Muscular Dystrophy 25th Annual Conference
  10. Vertex Expands Collaboration With CRISPR, Acquires Exonics
  11. Edited Transcript of CATB earnings conference call or presentation 14-May-19 12:30pm GMT
  12. SV Life Sciences Advisers, LLC Buys Catabasis Pharmaceuticals Inc, Sells KalVista ...
  13. Catabasis Pharmaceuticals Reports First Quarter 2019 Financial Results and Reviews Business Progress
  14. Catabasis Pharmaceuticals to Present Data from the MoveDMD® trial of Edasalonexent in Duchenne Muscular Dystrophy at the American Academy of Neurology 71st Annual Meeting
  15. Catabasis Pharmaceuticals to Report First Quarter 2019 Financial Results and Recent Corporate Developments on Tuesday, May 14th
  16. Should You Be Concerned About Catabasis Pharmaceuticals, Inc.'s (NASDAQ:CATB) Historical Volatility?
  17. Top Ranked Momentum Stocks to Buy for April 12th
  18. Catabasis Pharmaceuticals to Present at Upcoming Neuromuscular Translational Research Conference and MDA Clinical and Scientific Conference
  19. Proteostasis Plunges on Weak Data From Cystic Fibrosis Study
  20. Will Catabasis Pharmaceuticals Continue to Surge Higher?